GSK sues partner XenoPort over marketing allegations on RLS drug
GlaxoSmithKline (NYSE:GSK) is pushing back against drug partner XenoPort (NASDAQ:XNPT) over claims that GSK is not doing enough to sell the restless leg syndrome treatment they jointly developed. The British pharma giant has asked a federal court to rule that it has lived up to the terms of its partnership agreement with XenoPort and that […]